Seung TaeTaeLeeMDPh.D.

Oncology • Baltimore, MD

Hematologic Oncology

Clinical Fellow

Join to view full profile

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lee's full profile

Already have an account?

Office
22 S Greene St
Baltimore, MD 21201
Phone+1 410-328-8708

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Montefiore - Mount Vernon HospitalResidency, Internal Medicine, 2009 - 2012
Yonsei University College of MedicineClass of 1990

Certifications & Licensure

MD State Medical License 2015 - 2026
TX State Medical License 2012 - 2016
MA State Medical License 2011 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Recruiting
Phase 2, Phase 3
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

1 citations
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang
The New England Journal of Medicine. 2024-06-20
Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims ...
Dahlia Sano, Nicholas Liu, Scott Knowles, Joanna P MacEwan, Shu Wang
Current Oncology. 2024-05-02
Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
Gabriela Sanchez-Petitto, Olga G Goloubeva, Jack Masur, James Childress, Tahreem Iqbal
Leukemia Research. 2024-03-01

Abstracts/Posters

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...
Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Other Languages

Korean